Menstrual pain relief IUDs for men devised by Meliodays Medical and Celanese, free from hormones.
In a groundbreaking development, Meliodays Medical, a company dedicated to revolutionizing menstrual pain treatment, has partnered with Celanese Corporation. The collaboration aims to bring MelioOne, a hormone-free intrauterine device (IUD), to pre-clinical development [1][2][3].
MelioOne is designed specifically to alleviate menstrual pain without the need for contraception. Unlike traditional hormonal IUDs, MelioOne is an IUD that releases pain medication locally instead of hormones. This innovative approach targets the pain source directly, aiming to treat menstrual pain effectively with reduced systemic side effects compared to oral medications or hormone-based devices [1][2][3].
The VitalDose Drug Delivery Platform, developed by Celanese, has been used in approved medicines in the US and Europe for over two decades. This platform is particularly suitable for controlled release of various drug types and is used in various dosage forms. Celanese's expertise in specialty materials will be instrumental in the development of MelioOne [1][2][3].
"We are excited about collaborating with Meliodays in the early development of MelioOne," Brian Duke, Sr. Marketing Manager Pharmaceutical Solutions at Celanese, expressed. Duke's team at Celanese is proud of the VitalDose Drug Delivery Platform's long-term use in patient-oriented therapies, providing practical and effective treatment for women [1][2][3].
More than 80% of menstruating individuals experience cramps and pain during their period. Meliodays is addressing this high unmet medical need by focusing on an effective menstrual pain treatment without relying on hormones or systemic pain medications [1][2][3].
Simone Sabbione, CEO and co-founder of Meliodays, stated, "The cooperation with Celanese is a significant step in developing MelioOne towards a market-ready therapy." MelioOne, in collaboration with Celanese, aims to enable a pain-free period for menstruating individuals without disrupting the natural cycle [1][2][3].
The VitalDose Drug Delivery Platform will continue to be driven for application in therapies for women and anywhere long-term drug release offers benefits. This partnership between Meliodays and Celanese is a milestone in Meliodays' mission to revolutionize menstrual pain treatment [1][2][3].
[1] Source 1 [2] Source 2 [3] Source 3
The collaboration between Meliodays Medical and Celanese Corporation is significant in the development of MelioOne, a health-and-wellness product aimed at addressing women's health issues, specifically menstrual pain. Celanese's VitalDose Drug Delivery Platform, a long-standing platform in patient-oriented therapies, will be crucial in the pre-clinical development of MelioOne.
